AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38961501 — intervention group
Group type: COMPARATOR
Intervention: Standard care relying on clinician initiative to request interpreter services
Number of subjects: 35
Study 38961532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ECG (positive results)
Number of subjects: 2457
Study 38961532 — intervention group
Group type: EXPERIMENTAL
Intervention: Having at least two CVD risk factors
Number of subjects: 2457
Study 38962217 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered dance
Number of subjects: 52
Study 38962217 — intervention group
Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52
Study 38962436 — intervention group
Group type: EXPERIMENTAL
Intervention: GOE (900 mg/day)
Number of subjects: 145
Study 38962436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 38962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically Assisted Reproduction (MAR) for men
Number of subjects: 265
Study 38962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically Assisted Reproduction (MAR) for women
Number of subjects: 265
Study 38962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic pregnancies in women with PCD
Number of subjects: 265
Study 38962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility prevalence in men with PCD
Number of subjects: 265
Study 38962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility prevalence in women with PCD
Number of subjects: 265
Study 38962958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified intervention with a support partner
Number of subjects: 94
Study 38962958 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50) setting step goals and receiving daily feedback
Number of subjects: 94
Study 38963325 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of handgrip strength (HGS) with Jamar dynamometers and feedback about normal values for age and sex.
Number of subjects: 334
Study 38963325 — intervention group
Group type: COMPARATOR
Intervention: Standard check-ups (control group).
Number of subjects: 334
Study 38963325 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of HGS and feedback to patients with T2DM.
Number of subjects: 334
Study 38963325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low inclusion HGS.
Number of subjects: 334
Study 38963459 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone 1000 mg once daily
Number of subjects: 81
Study 38963477 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group psychoeducational intervention delivered in Spanish, including a video testimonial and facilitated discussion.
Number of subjects: 19
Study 38963477 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interviews with participants.
Number of subjects: 19
Study 38963556 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention
Number of subjects: 614
Study 38963556 — intervention group
Group type: COMPARATOR
Intervention: Baseline SCr/Q-height and SCr/Q-age
Number of subjects: 614
Study 38963583 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood (AB) injection: 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl
Number of subjects: 120
Study 38963583 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) injection: 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl
Number of subjects: 120
Study 38963583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection (AB + CS): 1 ml each of autologous venous blood and 40 mg methylprednisolone acetate along with 1 ml of 2% prilocaine HCl
Number of subjects: 120
Study 38963656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 94
Study 38963694 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-based video analysis
Number of subjects: 46
Study 38963694 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-CV collaboration
Number of subjects: 46
Study 38963694 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-based analysis
Number of subjects: 46
Study 38963694 — intervention group
Group type: COMPARATOR
Intervention: Comparison of early and late EEA videos
Number of subjects: 46
Study 38963799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesional skin of CSU patients
Number of subjects: 23
Study 38963799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlesional skin of CSU patients
Number of subjects: 23
Study 38963799 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 38963866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study 38963866 — intervention group
Group type: COMPARATOR
Intervention: Control details not available
Number of subjects: 0
Study 38964203 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary polyphenols (TPE)
Number of subjects: 662
Study 38964333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (LDRT) plus immune checkpoint inhibitors (ICI)
Number of subjects: 15
Study 38964333 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic LDRT plus chemoimmunotherapy
Number of subjects: 15
Study 38964353 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 108
Study 38964353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 38964361 — intervention group
Group type: EXPERIMENTAL
Intervention: V116 (21-valent pneumococcal conjugate vaccine)
Number of subjects: 2663
Study 38964361 — intervention group
Group type: COMPARATOR
Intervention: PCV20 (active comparator)
Number of subjects: 2663
Study 38964420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran 25 mg
Number of subjects: 40
Study 38964420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran 100 mg
Number of subjects: 40
Study 38964420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran 200 mg
Number of subjects: 40
Study 38964420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38964420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran
Number of subjects: 40
Study 38964630 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Social Intervention (ESI)
Number of subjects: 207
Study 38964630 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 207
Study 38964630 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Attention Symbolic Play Engagement and Regulation (JASPER)
Number of subjects: 207
Study 38964630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study 38964794 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy with double flap technique (LPG-DFT)
Number of subjects: 216
Study 38964794 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total gastrectomy with Roux-en-Y (LTG-RY)
Number of subjects: 216
Study 38964794 — intervention group
Group type: EXPERIMENTAL
Intervention: LPG-DFT
Number of subjects: 216
Study 38964797 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher patient-to-nurse ratio
Number of subjects: 217714
Study 38964799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, non-contrast-enhanced thoracic CT scans
Number of subjects: 220
Study 38964799 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid molecular sputum analysis using the BIOFIRE® FILMARRAY® pneumonia
Number of subjects: 220
Study 38964799 — intervention group
Group type: COMPARATOR
Intervention: Standard microbiological processing alone (no FAPP)
Number of subjects: 220
Study 38964803 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-testing
Number of subjects: 0
Study 38964802 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) integrated with conventional bronchoscopy
Number of subjects: 208
Study 38964802 — intervention group
Group type: COMPARATOR
Intervention: Conventional bronchoscopy without nCLE
Number of subjects: 208
Study 38964802 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 208
Study 38964845 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound diagnosis of isolated RAA
Number of subjects: 309
Study 38964854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (C-EMR)
Number of subjects: 177
Study 38964854 — intervention group
Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (H-EMR)
Number of subjects: 177
Study 38965031 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy (LDL-C goal of 50-70 mg/dl)
Number of subjects: 822
Study 38965031 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin therapy
Number of subjects: 822
Study 38965184 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluations of safety of the participant's current social and physical environment
Number of subjects: 286
Study 38965184 — intervention group
Group type: COMPARATOR
Intervention: Objective measures of neighborhood-level disorder
Number of subjects: 286
Study 38965462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 8
Study 38965464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful walking intervention (24 sessions over 3 months)
Number of subjects: 114
Study 38965464 — intervention group
Group type: COMPARATOR
Intervention: Delayed mindful walking group (control)
Number of subjects: 114
Study 38965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 40
Study 38965499 — intervention group
Group type: COMPARATOR
Intervention: Standard training (active control)
Number of subjects: 40
Study 38965541 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-inhaler triple therapy (SITT)
Number of subjects: 300
Study 38965541 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart inhalers
Number of subjects: 300
Study 38965541 — intervention group
Group type: EXPERIMENTAL
Intervention: SITT with digital support through a smart inhaler and an e-health platform
Number of subjects: 300
Study 38965541 — intervention group
Group type: COMPARATOR
Intervention: Multi-inhaler triple therapy (MITT)
Number of subjects: 300
Study 38965550 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP followed by erythritol subgingival air polishing
Number of subjects: 24
Study 38965550 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP followed by diode laser application
Number of subjects: 24
Study 38965550 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 24
Study 38965566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) for ME/CFS
Number of subjects: 84
Study 38965566 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (CPET) for CTL
Number of subjects: 84
Study 38965566 — intervention group
Group type: COMPARATOR
Intervention: Matched case-control pairs (n = 55) for aerobic capacity, age, and sex
Number of subjects: 84
Study 38965587 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT + TA + QA
Number of subjects: 63
Study 38965587 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation activities completed
Number of subjects: 63
Study 38965587 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived positive characteristics of the Body Project
Number of subjects: 63
Study 38965611 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 40 mg of furosemide intravenously over 10 minutes after fURS
Number of subjects: 100
Study 38965611 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 38965611 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 40 mg of furosemide
Number of subjects: 100
Study 38965611 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment with an alpha-blocker
Number of subjects: 100
Study 38965611 — intervention group
Group type: COMPARATOR
Intervention: Imaging analysis by urologist
Number of subjects: 100
Study 38965612 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept-guided, personalised, motor-cognitive exergame training (twice per week for 30 to 40 minutes)
Number of subjects: 38
Study 38965612 — intervention group
Group type: COMPARATOR
Intervention: Usual care without additional intervention(s)
Number of subjects: 38
Study 38965976 — intervention group
Group type: EXPERIMENTAL
Intervention: APS+HIVST
Number of subjects: 3646
Study 38965976 — intervention group
Group type: COMPARATOR
Intervention: Standard APS
Number of subjects: 3646
Study 38966081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame-based motor-cognitive training on a labile surface
Number of subjects: 30
Study 38966081 — intervention group
Group type: COMPARATOR
Intervention: Stable surface training (Control Group)
Number of subjects: 30
Study 38966095 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine amoxicillin
Number of subjects: 2399
Study 38966095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study 38966255 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in internalized weight stigma (IWS) at week 20
Number of subjects: 0
Study 38966255 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial reductions in internalized weight stigma (IWS)
Number of subjects: 0
Study 38966802 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS) combined with cognitive Virtual Reality Rehabilitation System (VRRS)
Number of subjects: 109
Study 38966802 — intervention group
Group type: COMPARATOR
Intervention: placebo tDCS combined with VRRS
Number of subjects: 109
Study 38966802 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive TR
Number of subjects: 109
Study 38966802 — intervention group
Group type: EXPERIMENTAL
Intervention: at-home unstructured cognitive stimulation
Number of subjects: 109
Study 38966802 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive treatment as usual
Number of subjects: 109
Study 38966851 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg Moxidectin (MOX)
Number of subjects: 72
Study 38966851 — intervention group
Group type: COMPARATOR
Intervention: 150 µg/kg Ivermectin (IVM)
Number of subjects: 72
Study 38966990 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan plus tadalafil combination therapy
Number of subjects: 148
Study 38967389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent only (AO) exercise intervention
Number of subjects: 116
Study 38967389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent + Parent (A + P) exercise intervention
Number of subjects: 116
Study 38967389 — intervention group
Group type: COMPARATOR
Intervention: Both AO and A + P arms
Number of subjects: 116
Study 38967583 — intervention group
Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI) use
Number of subjects: 73
Study 38967583 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 73
Study 38967583 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 73
Study 38967583 — intervention group
Group type: EXPERIMENTAL
Intervention: Private health insurance
Number of subjects: 73
Study 38967583 — intervention group
Group type: EXPERIMENTAL
Intervention: >16 educational years
Number of subjects: 73
Study 38967589 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Number of subjects: 234
Study 38967589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-C3 and ELF score
Number of subjects: 234
Study 38967722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasensitive detection method
Number of subjects: 0
Study 38967722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38967884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 93
Study 38967884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 38967926 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management (CDCM) for 6 months
Number of subjects: 308
Study 38967927 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 1113
Study 38967927 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 1113
Study 38967927 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal change in EtCO2
Number of subjects: 1113
Study 38967927 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope of EtCO2
Number of subjects: 1113
Study 38967929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic formulation consisting of 8 strains from 5 different genera
Number of subjects: 350
Study 38967929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 38968138 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-255 with CAR19-22
Number of subjects: 11
Study 38968138 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 11
Study 38968138 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 11
Study 38968243 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (supervised exercise with laser-guided feedback and interferential current therapy); 8 treatment sessions (twice per week) over 4 weeks
Number of subjects: 31
Study 38968243 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 31
Study 38968400 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful neuropathy (probable or definite NeuP)
Number of subjects: 1181
Study 38968400 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (random forest)
Number of subjects: 1181
Study 38968400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression
Number of subjects: 1181
Study 38968400 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest
Number of subjects: 1181
Study 38968414 — intervention group
Group type: EXPERIMENTAL
Intervention: LQ cut-off criterion of +/-60 for mixed-handedness
Number of subjects: 600
Study 38968414 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of hand preference and hand performance data
Number of subjects: 600
Study 38968414 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for a consensus on mathematical determination of ambidexterity
Number of subjects: 600
Study 38968425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief Right Unilateral ECT with Frontoparietal Electrode Placement
Number of subjects: 0
Study 38968425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief Right Unilateral ECT with Temporoparietal Electrode Placement
Number of subjects: 0
Study 38968520 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib maintenance therapy
Number of subjects: 23
Study 38968568 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET imaging
Number of subjects: 0
Study 38968568 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA histopathology
Number of subjects: 0
Study 38968568 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted therapeutics
Number of subjects: 0
Study 38968599 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Number of subjects: 45
Study 38968807 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (NFB) from the superior temporal gyrus (STG)
Number of subjects: 22
Study 38968807 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled neurofeedback from the motor cortex
Number of subjects: 22
Study 38969081 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PAD (ABI ≤0.90)
Number of subjects: 2209
Study 38969081 — intervention group
Group type: COMPARATOR
Intervention: Participants without PAD (normal ABIs)
Number of subjects: 2209
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE-treated donor livers (DBD)
Number of subjects: 1202
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE-treated donor livers (DCD)
Number of subjects: 1202
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft loss due to PNF (DBD)
Number of subjects: 1202
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft loss due to IC (DBD)
Number of subjects: 1202
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft loss due to PNF (DCD)
Number of subjects: 1202
Study 38969242 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft loss due to IC (DCD)
Number of subjects: 1202
Study 38969374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg, max 50 mg) over 40 minutes
Number of subjects: 20
Study 38969374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL/kg normal saline, max 50 mL) over 40 minutes
Number of subjects: 20
Study 38969378 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing cream gel (SCG)
Number of subjects: 0
Study 38969378 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 38969497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1395
Study 38969791 — intervention group
Group type: EXPERIMENTAL
Intervention: Rash management guide provided to patients in Apa-RP
Number of subjects: 0
Study 38969791 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vigilance and proactive management
Number of subjects: 0
Study 38969866 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA and small molecule inhibitors
Number of subjects: 0
Study 38969866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken embryo chorioallantoic membrane (CAM) model
Number of subjects: 0
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic vinorelbine (NVB) monotherapy (n=11)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: NVB plus anti-PD-1 toripalimab (n=7)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic bevacizumab, NVB and toripalimab (n=27)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cisplatin, NVB and toripalimab (n=26)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n=26)
Number of subjects: 97
Study 38969879 — intervention group
Group type: EXPERIMENTAL
Intervention: VEX cohort (n=26)
Number of subjects: 97